Hetero Labs' Acarbose-Sitagliptin-Metformin FDC Rejected by CDSCO Panel Over GI Risk
New Delhi: In a setback to Hetero Labs Limited, the Subject Expert Committee (SEC) functional under the Central Drugs Standard Control Organisation (CDSCO) has declined to recommend approval for the fixed-dose combination (FDC) of Acarbose, Sitagliptin Phosphate Monohydrate, and Metformin Hydrochloride film-coated tablets proposed by the drugmaker.
The proposal was reviewed at the recent SEC meeting for Endocrinology and Metabolism held on 11th June 2025, where the firm presented the FDC along with justification for the combination. This review was taken up in light of an earlier SEC recommendation dated 13.11.2024.
Following detailed deliberation, the committee opined that:
“The firm did not present the rationality of the three drug combination for better efficacy and safety.”
Additionally, the expert panel expressed concerns about gastrointestinal side effects, stating:
“GI adverse effect will be high for proposed three drug combination.”
In view of the above, the committee did not recommend approval for the proposed FDC.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.